Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL745207 | 0.78 | EPHX1 (0.50) | EPHX1SIGMAR1SLC6A2TAAR1MAOA | |
| SCHEMBL8726699 | 0.78 | EPHX1 (0.50) | CSNK1EEPHX1SIGMAR1SLC6A2TAAR1 | |
| SCHEMBL10512424 | 0.76 | MEN1 (0.46) | CSNK1EEPHX1SIGMAR1SLC6A2TAAR1 | |
| SCHEMBL3275777 | 0.76 | LTA4H (0.46) | CSNK1ESIGMAR1SLC6A2TAAR1MAOA | |
| SCHEMBL28475117 | 0.73 | CSNK1E (0.50) | CSNK1EEPHX1SIGMAR1SLC6A2TAAR1 | |
| SCHEMBL7759621 | 0.71 | CSNK1E (0.47) | CSNK1E | |
| SCHEMBL8072690 | 0.71 | LTA4H (0.42) | CSNK1ESIGMAR1SLC6A2TAAR1MAOA | |
| SCHEMBL3270666 | 0.71 | CSNK1E (0.46) | CSNK1ESIGMAR1SLC6A2TAAR1MAOA | |
| SCHEMBL7924701 | 0.70 | ALDH1A1 (0.41) | CSNK1ESIGMAR1 | |
| SCHEMBL21243278 | 0.70 | SIGMAR1 (0.42) | CSNK1ESIGMAR1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0947513-B1 | TRICYCLIC AMINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-6586604-B2 | Antimicrobial activity versus gram negative and gram positive bacteria | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-07-01 | — | — | US | disclosed |
| US-6384050-B1 | GASTROINTESTINAL DISORDERS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| US-20010037030-A1 | Tricyclic amine derivatives | TAKEMURA MAKOTO (JP) | 2001-11-01 | — | — | US | disclosed |
| EP-0947513-A1 | TRICYCLIC AMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037030-A1 | Tricyclic amine derivatives | Q6ZSR9, TOP2A, TOP1 | CSNK1E 1340/4885EPHX1 2918/4885SIGMAR1 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.